| Autor: |
Petkov D; 57146Charles River Laboratories, Edinburgh, United Kingdom., Patrick DJ; 537465Charles River Laboratories, Mattawan, MI, USA., Rogerson P; 57146Charles River Laboratories, Edinburgh, United Kingdom., Rehagen D; 537465Charles River Laboratories, Mattawan, MI, USA., Hennig G; 70294Charles River Laboratories, Senneville, Quebec, Canada., Bradley A; 57146Charles River Laboratories, Edinburgh, United Kingdom., Howroyd P; 57146Charles River Laboratories, Edinburgh, United Kingdom., Czajkowski M; Melissa Czajkowski, 26135Charles River Laboratories, 's-Hertogenbosch, the Netherlands. Petkov is now with Frontage Laboratories, Concord, OH, USA; Patrick is now with Eli Lilly and Company, Indianapolis, IN, USA., Decker J; 537465Charles River Laboratories, Mattawan, MI, USA., Aboulmali A; 70294Charles River Laboratories, Senneville, Quebec, Canada., Balmer B; 537465Charles River Laboratories, Mattawan, MI, USA. |
| Abstrakt: |
Aneurysms of the ascending aorta, unrelated to xenobiotic administration, are described in 5 rats and 2 mice in nonclinical safety studies conducted at Charles River Laboratories (CRL) sites over the past 10 years. The most prominent microscopic finding was focal dilation with disruption of the wall of the ascending aorta with chronic adventitial inflammation or fibroplasia. The pathogenesis of this finding is unknown. There were no associated macroscopic findings, clinical abnormalities, or vascular lesions elsewhere. The results of a search of historical control data from toxicology studies of 1 day to 72 weeks' duration performed at CRL for aortic findings from 5900 mice and 23,662 rats are also reported. Aortic lesions are uncommon in mice and rats used in nonclinical safety studies, but toxicologic pathologists should be aware that aneurysms of the ascending aorta with fibroplasia and inflammation in the aortic wall and adventitia may occur spontaneously or iatrogenically, as they have the potential to impact interpretation in toxicology studies. |
